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Abstract
Several reports have demonstrated a role for aberrant NOTCH signaling in melanoma genesis and progression, prompting
us to explore if targeting this pathway is a valid therapeutic approach against melanoma. We targeted NOTCH signaling
using RO4929097, a novel inhibitor of gamma secretase, which is a key component of the enzymatic complex that cleaves
and activates NOTCH. The effects of RO4929097 on the oncogenic and stem cell properties of a panel of melanoma cell lines
were tested both in vitro and in vivo, using xenograft models. In human primary melanoma cell lines, RO4929097 decreased
the levels of NOTCH transcriptional target HES1. This was accompanied by reduced proliferation and impaired ability to
form colonies in soft agar and to organize in tridimensional spheres. Moreover, RO4929097 affected the growth of human
primary melanoma xenograft in NOD/SCID/IL2gammaR-/- mice and inhibited subsequent tumor formation in a serial
xenotransplantation model, suggesting that inhibition of NOTCH signaling suppresses the tumor initiating potential of
melanoma cells. In addition, RO4929097 decreased tumor volume and blocked the invasive growth pattern of metastatic
melanoma cell lines in vivo. Finally, increased gene expression of NOTCH signaling components correlated with shorter post
recurrence survival in metastatic melanoma cases. Our data support NOTCH inhibition as a promising therapeutic strategy
against melanoma.
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Introduction
The incidence of melanoma has been constantly increasing
during the last decades [1]. Adjuvant therapy after complete
resection is recommended for thick primary melanoma with
lymph node metastases, because recurrence rates are relatively
high and overall survival is poor [2]. However, IFNalpha remains
the only approved adjuvant therapy, which provides a modest
disease-free survival benefit [3]. Furthermore, it is especially
concerning that the conventionally used drugs for metastatic
melanoma include dacarbazine and IL-2, both of which cause
poor (,15% of cases) and transient responses [4]. Although
promising therapeutic responses have been observed in recent
clinical trials using the BRAF inhibitor Vemurafenib (PLX4032)
and the monoclonal antibody against CTLA-4 Ipilimumab, both
recently approved by the FDA, emergence of resistance and severe
side effects have already been confronted [5,6,7,8,9,10].
The NOTCH signaling pathway, which plays a role in
organogenesis and cell fate determination during embryogenesis,
involves four NOTCH transmembrane receptors (NOTCH 1-4)
[11]. Binding of DELTA (DLL 1/3/4) or JAGGED (JAG 1/2)
ligands makes the receptors susceptible to metalloprotease- and
gamma secretase-mediated proteolytic cleavage. This cleavage results
in the release of NOTCH intracellular domain (N
IC)f r o mt h ep l a s m a
membrane and its translocation into the nucleus. Here, N
IC mediates
the transcription of target genes, including basic helix-loop-helix
transcription factors of the hairy and enhancer of split (HES) family
and the HES-related repressor protein (HERP/HRT/HEY) family.
Aberrant NOTCH signaling has been recently linked to many
malignancies including melanoma, where it plays a role in
progression and possibly in development [12,13]. Mechanistically,
NOTCH signaling relies on crosstalk with the Wnt/b-catenin, the
MAPK/AKT, the BRN2/MITF and the NODAL pathways in
order to elicit its biological functions [12,14,15,16,17].
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cell-like properties in different cancer types, such as breast cancer
and glioma (reviewed in ref. [18]). Identification of stem cell-like
tumor initiating cells has been of major interest in melanoma.
Although there is an ongoing debate about the frequency and
identity of melanoma initiating cells [19,20,21,22,23], the inability
to eradicate this subpopulation is thought to be a reason for the
failure of current treatment strategies [24]. Therefore, NOTCH
inhibition in melanoma, possibly through the targeting of tumor
initiating cells, can be foreseen as a new and promising therapeutic
strategy.
Essential to NOTCH signaling is the catalytic cleavage of
NOTCH receptor by the gamma secretase complex. Different
inhibitors of gamma secretase have been developed (see ref. [18]
for a list). These inhibitors have been tested in vitro on a variety of
cell lines, including melanoma [12,13,18,25]. Clinical data have
been supplied mostly by trials in adult T Cell leukemia (ALL), but
efficacy has been hindered by significant gastrointestinal toxicities
associated with treatment [26]. However, RO4929097 is a novel
gamma secretase inhibitor with an improved clinical toxicity
profile [27]. Here, we report the preclinical effects of RO4929097
on both primary and metastatic melanoma cells. In particular, we
show for the first time that the inhibition of NOTCH signaling has
an impact on the tumor initiating properties of melanoma cells.
Results
RO4929097 affects the oncogenic and stem cell-like
properties of primary melanoma cells in vitro
In order to evaluate the potential use of RO4929097 in the
adjuvant setting, the drug was initially tested on a panel of primary
melanoma cell lines. WM35, WM98.1, WM115, WM983A and
WM3248 were chosen because of their aggressive phenotype, as
indicated by their ability to form colonies in soft agar and to
organize in spheres (Figure S1), which are nonadherent 3D
structures enriched in melanoma initiating cells and characterized
by increased differentiation capacity in vitro and tumorigenic
potential in vivo [28,29].
Upon RO4929097 treatment, the selected melanoma cell lines
showed downregulation of NOTCH downstream effector HES1
(Figure 1A), confirming the ability of the drug to affect the
NOTCH signaling pathway. The impairment of NOTCH
signaling was associated with a significant reduction in cell
proliferation (Figure 1B) and in anchorage independent growth
(Figure 1C). We then tested the ability of RO4929097 to impair
the formation of melanospheres. We indeed found a decrease in
the amount of melanospheres formed upon RO4929097 treatment
in primary melanoma cell lines (Figure 1D).
Taken together these results suggest that RO4929097 is able to
affect the oncogenic and stem cell-like properties of melanoma
cells in vitro.
RO4929097 impairs the growth of primary melanoma
cells in vivo
To further validate the effects of NOTCH pathway inhibition,
we investigated the effects of RO4929097 on the growth of the
primary melanoma cell line WM3248 in NOD/SCID/IL2gam-
maR-/- (NOG) mice. Once measurable tumors were established,
we randomly distributed the mice into groups to receive either
vehicle control or RO4929097 by daily oral administration (Figure
S2A). In accordance with our in vitro data, we found a decrease in
tumor growth with RO4929097 treatment, which was more
appreciable after tumors were extracted for weight assessment
(Figure 2A, B). RO4929097-treated tumors also displayed lower
expression of putative melanoma stem cell markers CD166, CD271
and JARID1B [19,21,30] compared to vehicle-treated ones
(Figure 2C). In order to formally prove that the decrease in these
markers is associated with a diminished tumor-initiating ability, we
used a serial xenotransplantation assay [31]. We resected primary
tumors from RO4929097- or vehicle-treated mice and dissociated
the cells for re-implantation into NOG mice. We compared two
different cellular concentrations, 10
5 and 10
4 cells per flank.
Secondary tumors did not receive any further treatment with
either vehicle or RO4929097, while their intrinsic growth
properties were monitored (Figure S2A). At the concentration of
10
5 injected cells per flank, we did not find a significant difference
between vehicle- and RO4929097-treated cells in time to
secondary tumor formation. However, the percentage of second-
ary tumors formed by RO4929097-treated cells was lower
(Figure 2D, left). Furthermore, the secondary tumors formed by
RO4929097-treated cells were smaller (Figure 2E, F). Strikingly, a
significant delay in tumor formation by the RO4929097-treated
cells compared to the vehicle-treated ones was observed in mice
injected with 10
4 cells (Figure 2D, right). Nearly 40 days after
implantation, only 1/8 flanks injected with RO4929097-treated
cells had developed measurable tumors as compared to 6/8
injected with vehicle-treated cells. All together these results
indicate that RO4929097 is able to affect the tumorigenic
potential of melanoma cells in vivo.
RO4929097 impairs the growth of metastatic melanoma
cells in vivo
We also tested the effects of RO4929097 on metastatic
melanoma cell lines using two in vivo xenograft models. We first
assessed the impact of RO4929097 on tumor onset by treating
NOG mice with the compound for 12 days, starting 7 days after
flank injection of 5B1 melanoma cells (Figure S2B). In this
experimental setting, we found a significant delay in tumor
formation in RO4929097-treated mice compared to vehicle
treated ones (Figure 3A). RO4929097-treated tumors were
characterized by reduced proliferative index, as revealed by Ki-
67 staining (Figure 3B). We then assessed the impact of
RO4929097 treatment on the growth of pre-existing tumors, by
initiating the treatment only after measurable tumors were
established (Figure S2C). RO4929097 treatment negatively
affected the volume (Figure 3C) and especially the weight
(Figure 3D) of A375 tumors xenografted into NOG mice, without
increasing the number of apoptotic cells (Caspase 3 staining on
resected tumors, not shown). A different in vivo growth pattern
associated with RO4929097 treatment was also observed:
compound-treated tumors grew along the subcutaneous dermal
borders, as opposed to vehicle-treated tumors that consistently
invaded the peritoneum (Figure 3E). The expression of the
NOTCH targets HES1 and HEY1 was reduced in RO4929097-
treated tumors, together with that of putative melanoma stem cell
markers (Figure 3F). Previous studies have shown significant
toxicity, particularly secretory diarrhea, associated with gamma
secretase inhibition. In contrast, we did not observe any significant
weight changes or overt abnormalities in the organs of
RO4929097-treated mice compared to vehicle-treated ones
(Figure S3).
NOTCH activity predicts melanoma patient outcome
The analysis of gene expression arrays recently published by our
group and others [32,33,34] shows that several NOTCH signaling
pathway components are overexpressed in primary as well as in
metastatic melanoma compared to melanocytic controls (Figure 4A
and Figure S4), confirming the notion that NOTCH signaling
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knowledge, a potential association between aberrant NOTCH
signaling and prognosis in melanoma patients has not been shown.
Using the Affymetrix expression profile of 44 metastatic melanoma
samples from patients followed clinically for a median of 20
months (2–38 months range) [37], we examined whether NOTCH
Figure 1. RO4929097 inhibits proliferation, anchorage independent growth, and sphere formation of primary melanoma cells in
vitro. (A) RO4929097 causes a decrease in the levels of NOTCH downstream target HES1. WM35, WM98.1, WM115, WM983A and WM3248 cells were
treated with DMSO (white bars) or 10 uM RO492907 (black bars) for 24 h. At that time, RNA was collected and HES1 levels were measured by qRT-
PCR. The mean6s.d. of 3 independent experiments is reported. (B) RO4929097 inhibits cell proliferation. The indicated cell lines were treated with
DMSO (white circles) or 10 uM RO4929097 (black circles). A representative curve of three independent experiments is reported. (C) RO4929097
inhibits anchorage independent growth. White bars: DMSO treated cells; black bars: RO4929097 treated cells. The mean6s.d. of three independent
experiments is reported. Right panels show representative images of WM983A cells. (D) RO4929097 impairs the formation of melanospheres.
Representative pictures of one among 3 independent experiments are shown. T test, *p,0.05; **p,0.005; ***p,0.001.
doi:10.1371/journal.pone.0025264.g001
Figure 2. RO4929097 impairs the growth of primary melanoma cells in vivo. (A–C) Primary tumor formation of vehicle- and RO4929097-
treated WM3248 cells. (A)5 610
6 WM3248 primary melanoma cells were injected in the flank of NOG mice (n=20). Once the tumors became
measurable, mice were randomized in two groups and vehicle (n=10) or RO4929097 (n=10) was administered orally at 10 mg/Kg/day for 30 days.
Tumor volume was measured every 2–3 days. White circles: vehicle-treated mice; black circles: RO4929097-treated mice. (B) At the end of the
treatment period, tumors were excised and weighed. White bar: vehicle-treated mice; black bar: RO4929097-treated mice. (C) Levels of melanoma
stem cell markers CD166, CD271 and JARID1B in WM3248 xenografts measured by qRT-PCR. White bars: vehicle-treated tumors; black bars:
RO4929097-treated tumors. (D–F) Secondary tumor formation of vehicle and RO4929097-treated WM3248 cells. (D) White bars: secondary tumors
formed by vehicle-treated primary tumors; black bars: secondary tumors formed by RO4929097-treated primary tumors. (E) Volume and (F) weight of
the secondary tumors formed by 10
5 WM3248 cells previously treated with vehicle (white circles/bar) or RO4929097 (black circles/bar). Tumor volume
was measured every 2–3 days starting at 30 days post injection. At 45 days after the injection, tumors were excised and the weight was measured. T
test, *p,0.05; **p,0.005; ***p,0.001.
doi:10.1371/journal.pone.0025264.g002
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6 5B1 metastatic melanoma cells were injected in
the flank of NOG mice (n=20). Before tumors became measurable, mice were randomized in two groups and vehicle (n=10) or RO4929097 (n=10)
was administered orally at 10 mg/Kg/day for 12 days. (A) Tumor volume, measured every 2–3 days starting 3 days after the end of the treatment.
White circles: vehicle-treated mice; black circles: RO4929097-treated mice. (B) Percentage of Ki-67-positive cells in vehicle-treated (white circles) and
RO4929097-treated (black circles) tumors. Immunohistochemistry was performed on tumor excised twenty-five days after the end of the treatment.
(C–F)2 610
6 A375 metastatic melanoma cells were injected in the flanks of NOG mice (n=12). As soon as tumors became measurable, mice were
randomized in two groups, and vehicle (n=6) or RO4929097 (n=6) was administered orally at 10 mg/Kg/day for 2 weeks. (C) Tumor volume,
measured every 2–3 days during the two weeks of treatment. White circles: vehicle-treated mice; black circles: RO4929097-treated mice. (D) Tumor
weight, measured when the tumors were excised at the end of the 2 weeks of treatment. White bar: vehicle-treated mice; black bar: RO4929097-
treated mice. (E) Invasive features (dermal attachment versus peritoneal invasion) of vehicle-treated and RO4929097-treated tumors. (F) qRT-PCR
analysis of NOTCH downstream effectors HES1 and HEY1 and of melanoma stem cell markers CD166, CD271 and JARID1B in vehicle-treated (white
bars) and RO4929097-treated (black bars) tumors. T test, *p,0.05; **p,0.005; ***p,0.001.
doi:10.1371/journal.pone.0025264.g003
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25264Figure 4. NOTCH pathway is upregulated in human melanoma metastasis and correlates with worse prognosis. (A) mRNA array
analysis of NOTCH pathway members. Affymetrix U133A 2.0 array performed on 4 melanocyte controls (2 normal human melanocytes and 2
immortalized melanocytes), 4 primary and 14 metastatic cell lines [34] reveals the upregulation of NOTCH pathway members, such as JAG1, JAG2,
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melanoma. We indeed found that higher HES1 and DLL3 levels
were significantly associated with decreased post recurrence
survival as continuous predictors in Cox regression analysis
(Figure 4B).
Discussion
The aggressiveness of melanoma, which is surprisingly high
considering that it is among a handful of cancers whose
dimensions are reported in millimeters, is due to the high degree
of heterogeneity and plasticity combined with the chemoresistance
of melanoma cells [38,39,40]. Therefore, new treatment strategies
that selectively target the most resistant cells within the tumors,
potentially the stem cell-like melanoma initiating cells, are urgently
needed [41,42].
RO4929097 has been previously shown to be a potent and
selective gamma secretase inhibitor with promising antitumoral
activity in vivo and without the toxicity associated with other
gamma secretase inhibitors [27]. Here, RO4929097 was shown
for the first time to affect the tumor initiating ability of melanoma
cells. We found that RO4929097 suppresses the oncogenic
properties of several primary melanoma cell lines, as indicated
by the decrease in proliferation and in the number of colonies
formed in soft agar by RO4929097-treated cells. More impor-
tantly, we found that RO4929097 impairs the formation of
melanospheres (Figure 1). In order to confirm in vivo that
RO4929097 can affect the tumor initiating ability of melanoma
cells, we used the serial xenotransplantation assay. This assay is the
gold standard in assessing self-renewal, which is the defining
property of cancer stem cells [31]. Strikingly, the serial
xenotransplantation assay showed a significant delay in tumor
formation by the RO4929097-treated cells compared to the
vehicle-treated ones (Figure 2). The decrease in size and incidence
and the increase in latency of the secondary tumors formed by
RO4929097-treated cells are particularly remarkable since we did
not sort these cells for any specific marker, such as CD271 and
ABCB5 [19,20]. Individual markers of tumor initiating cells have
been challenged by the experimental evidence that most
melanoma cells harbor tumorigenic capacity, irrespective of their
phenotypic characteristics [22]. Our data indicating that
RO4929097 can affect the tumorigenicity of melanoma cells
further support the inhibition of NOTCH signaling as a promising
therapeutic strategy for the eradication of melanoma, as suggested
for breast cancer and glioma [43,44,45].
Although it is important to understand alterations essential to
primary transformation, the clinical obstacle in melanoma
treatment is the dearth of effective therapeutics in the metastatic
setting. In addition to its role in melanomagenesis, aberrant
NOTCH signaling has been shown to promote metastasis in
melanoma and other cancers [12,46]. Due to all these findings, we
decided to test the efficacy of RO4929097 in vivo on metastatic
melanoma cell lines. We observed that RO4929097 not only
interferes with the ability of metastatic melanoma cells to form
tumors when injected into nude mice, but also impairs the growth
of pre-existing tumors (Figure 3). All together, these data lend
further support to the notion that NOTCH signaling can play a
role in advanced melanoma and offer a rationale to explore the
therapeutic potential of NOTCH inhibition in the metastatic
setting.
Finally, the analysis of gene expression arrays recently published
by our group and others showed that several NOTCH signaling
pathway components are overexpressed in metastatic cell lines in
comparison to melanocytes. Furthermore, we report for the first
time that aberrant NOTCH signaling can predict clinical outcome
in melanoma, with high HES1 and DLL3 levels associated with
shorter post recurrence survival (Figure 4). These results are in
agreement with data previously reported in other tumor types,
such as breast cancer [47,48] and neuroblastoma [49].
Molecular classification of melanoma is an emerging theme in
melanoma therapeutics, with BRAF and c-KIT mutation status
determining novel treatment options [50,51]. Although
RO4929097 shows antitumor activity in both primary and
metastatic cell lines, response to RO4929097 is not universal.
Not all melanoma cell lines are (equally) sensitive in all the assays,
as exemplified by the fact that some of the melanoma cell lines we
tested were not responsive to the compound (data not shown) and
by the different degree of reduction in proliferation and colony
formation in soft agar showed by the 5 responsive cell lines
reported in Figure 1. This differential sensitivity may be dependent
on a unique molecular signature. The signature of responders to
RO4929097 will emerge as clinical data accumulate from ongoing
trials with this compound in melanoma, and will help to define the
subset of patients that will benefit the most from RO4929097
treatment. These studies may also help to conceive combinatorial
treatments of RO4929097, which, even when effective, does not
cause a profound inhibition of tumor growth (Figure 1B, 2A,
3A, 3C), but is able to affect tumor initiating ability (Figure 2D),
with other drugs that, conversely, are more effective at preventing
tumor growth, but fail to decrease the tumor initiating ability.
Alternatively, RO4929097 could also be effective in the adjuvant
setting to prevent metastatic spread.
In summary, our preclinical studies support the gamma
secretase inhibition as a novel approach that is able to target the
melanoma initiating pool and offer insights into the clinical
potential of this new treatment strategy.
Materials and Methods
Human melanoma cell lines
Primary melanoma cell lines WM35, WM98.1, WM115,
WM983A and WM3248 were purchased from the Wistar Institute
(Philadelphia, PA) and cultured in Mel 2% medium [28]. A375
metastatic melanoma cell line was purchased from ATCC and
cultured in DMEM +10% FBS. WM239A/131/4-5B1 (5B1)
metastatic melanoma cell line, a kind gift from Robert S. Kerbel
(University of Toronto), was cultured in DMEM+10% FBS.
Quantitative real time PCR (qRT-PCR)
Total RNA was extracted using Trizol reagent according to the
manufacturer’s instructions. It was then subjected to DNase
treatment and retrotranscription (1ug RNA in a 20 ul reaction).
Real-time PCR of HES1, HEY1, CD166, CD271, and JARID1B
was performed using Sybr green fluorescence. 2 ul of RT were
used in a 20 ul reaction. GAPDH was used as an internal standard.
Relative quantification of gene expression was performed with the
DLL3, NOTCH3, HES1, HES2, HEY1 and HEY2 in melanoma. (B) Post recurrence survival of melanoma patients showing low and high levels of NOTCH
pathway members HES1 (left) and DLL3 (right). Previously published gene expression data of 44 metastatic melanoma tissue samples [37] were used
to define ‘‘low’’ and ‘‘high’’ expressor groups (upper panels, Wilcoxon test, ***p,0.001) and to generate Kaplan-Meier curves (lower panels, log-rank
test).
doi:10.1371/journal.pone.0025264.g004
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are described in Table S1.
Proliferation assay
Cells were seeded at 2.5610
3 cells per well on a 12-well dish in
triplicate. The day after (day 0), the medium was replaced, and
DMSO or 10 uM RO4929097 was added and changed every 3–4
days. At the indicated time points, cells were fixed in 10% formalin
solution and stored in PBS at 4uC. At day 18–24, all the plates
were stained with crystal violet. After color elution with 10% acetic
acid, optical density was read at 590 nm. A representative curve of
three independent experiments is reported.
Growth in semisolid medium
The bottom layer was obtained by covering 6-well dishes with
3 ml of 0.6% agar in MCDB 153 medium [28]. The day after,
5610
4 cells pre-treated for 24 h with 10 uM RO4929097 or
vehicle were seeded in triplicate in 2 ml Mel 2% medium
containing 0.3% agar and 10 uM RO4929097 or vehicle.
Colonies were counted after 3–4 weeks.
Melanosphere formation assay
Cells were seeded at a density of 5610
5 per 6 cm dish in Mel
2% medium. The day after, the medium was switched to ES cell
medium (hESCM4, Invitrogen) containing either DMSO or
10 uM RO4929097. The medium was left unchanged for two
weeks, and then half of the medium was changed once a week,
refreshing the drug. Spheres were visible in the DMSO treated
dishes after 6–12 weeks.
Serial xenotransplantation assay of WM3248 cells
5610
6 WM3248 primary melanoma cells were injected in the
flank of NOG mice (n=20). Once the tumors became measurable,
mice were randomized in two groups and vehicle (n=10) or
RO4929097 (n=10) was administered orally at 10 mg/Kg/day
according to the protocol described in [27]. Tumor volume was
measured every 2–3 days for a total of 30 days (Figure S2A). At the
end of the treatment period, tumors were excised and weighed. A
piece of the excised tumors was cut and used for RNA extraction
and qRT-PCR. The rest of the tumor was mechanically
dissociated and passed through 100 um and 40 um strainers (BD
Falcon). Viable cells were counted and 10
5 and 10
4 cells were re-
injected in the flanks of NOG mice (n=8) without any further
treatment with RO4929097. At the indicated time points, the
presence of tumor was checked. Tumor volume was measured
every 2–3 days starting at 30 days post injection. At 45 days after
the injection, tumors were excised and the weight was measured.
Xenograft assay of 5B1 and A375 cells
10
6 5B1 cells were injected in the flank of NOG mice (n=20).
Before tumors became measurable, mice were randomized in two
groups and vehicle (n=10) or RO4929097 (n=10) was admin-
istered orally at 10 mg/Kg/day for 12 days (Figure S2B). Twenty-
five days after the end of the treatment, tumor were excised,
formalin fixed and paraffin embedded.
2610
6 A375 cells were injected in the flanks of NOG mice
(n=12). As soon as tumors became measurable (60–100 mm
3),
mice were randomized in two groups, and vehicle (n=6) or
RO4929097 (n=6) was administered orally at 10 mg/Kg/day for
2 weeks (Figure S2C). Tumor volume was measured every 2–3
days during the two weeks of treatment. Tumor weight was
measured when the tumors were excised at the end of the 2 weeks
of treatment.
Ethics statement
Experiments were conducted following protocols approved by
the NYU Institutional Animal Care Use Committee (IACUC)
(protocol number 080109).
Immunohistochemistry (IHC)
Ki-67 IHC was performed using mouse anti-human Ki-67
monoclonal antibody (Neomarkers/Lab Vision, Fremont, CA,
USA). Sections were deparaffinized in xylene (3 changes),
rehydrated through graded alcohols (3 changes 100% ethanol, 3
changes 95% ethanol) and rinsed in distilled water. Heat-induced
epitope retrieval was performed in a 1200-Watt microwave oven
at 100% power in 10 mM citrate buffer pH 6.0 for 20 min.
Sections were allowed to cool down for 30 min and then rinsed in
distilled water. Antibody incubation and detection were carried
out at 37uC on a NEXes instrument (Ventana Medical Systems
Tucson, Arizona) using Ventana’s reagent buffer and detection
kits. Endogenous peroxidase activity was blocked with hydrogen
peroxide. Ki-67 was diluted 1:400 and incubated for 30 min at
room temperature. Biotinylated goat anti-mouse followed by
application of streptavidin-horseradish-peroxidase conjugate was
used to detect the primary antibody. The complex was visualized
with 3,3-diaminobenzidene and enhanced with copper sulfate.
Slides were washed in distilled water, counterstained with
hematoxylin, dehydrated and mounted with permanent media.
Appropriate positive controls were included with the study
sections. Blinded to mouse groups, an attending pathologist
(F.D.) scored the percentage of Ki-67-positive cells in each slide.
Analysis of previously published datasets
Gene expression data of 44 metastatic melanoma tissue samples
previously published by our group [37] were used to define ‘‘low’’
and ‘‘high’’ expressor groups for HES1 and DLL3 (Wilcoxon test)
and to generate Kaplan-Meier curves (log-rank test). The binary
classification of gene expression uses a cut-off point derived using
the statistical method described in [53], which is based on
maximizing the absolute value of log-rank statistic. Expression
values for both HES1 and DLL3 are statistically significant as
continuous predictors of survival in Cox proportional hazard
regression models (p values,0.03).
Supporting Information
Figure S1 Primary melanoma cell lines form spheres
when switched to ES medium. WM35, WM98.1, WM115,
WM983A and WM3248 (left panels) organize in three-dimen-
sional melanospheres (right panels, arrows) when switched to ES
medium.
(TIF)
Figure S2 Schemes of drug treatment and toxicity. (A)
Scheme of treatment for WM3248 xenograft. 5610
6 WM3248
primary melanoma cells were injected in the flanks of NOG mice
(10 per group). Once tumors were measurable, vehicle or
RO4929097 was administered orally at 10 mg/Kg/day for 30
days. At day 42, mice were sacrificed and the tumors dissected and
mechanically dissociated. 10
4 and 10
5 cells from vehicle and
compound treated tumors were injected in the flank of NOG mice
(8 flanks/group) and tumor formation was followed for 45 days. (B)
Scheme of treatment for 5B1 xenograft. 10
6 5B1 metastatic
melanoma cells were injected in the flank of NOG mice (10 per
group). Before tumors became measurable, vehicle or RO4929097
was administered orally at 10 mg/Kg/day for 12 days. Treatment
was stopped and tumor volume was started to be measured. (C)
Inhibition of NOTCH Pathway in Melanoma
PLoS ONE | www.plosone.org 8 September 2011 | Volume 6 | Issue 9 | e25264Scheme of treatment for A375 xenograft. 2610
6 A375 metastatic
melanoma cells were injected in the flank of NOG mice (6 per
group).Afterthetumorbecamemeasurable,vehicleorRO4929097
was administered orally at 10 mg/Kg/day for 2 weeks.
(TIF)
Figure S3 Toxicity of RO4929097. Throughout the treat-
ment period, mice treated with RO4929097 (black circles) did not
show any weight loss compared with the vehicle treated ones
(white circles).
(TIF)
Figure S4 Expression of Notch related genes in previ-
ously published data sets. (A) mRNA expression of the
NOTCH ligand DLL3 (left) and the NOTCH target gene HEY1
(right). One-way variance ANOVA test was applied. (B) mRNA
expression of the ligand DLL3 (up, left) and the targets HEY1 (up,
right), HEY2 (down, left) and N-Cadherin (down, right). Unpaired
t test with Welch’s correction was applied. NHEM indicates the
expression in the melanocytic lineage.
(TIF)
Table S1 Real time PCR primers. List of primer pairs used
to amplify the indicated mRNAs by quantitative PCR.
(TIF)
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